Summary:
- Moderna, a biotechnology company, has provided an update on its investigational pandemic influenza program. This program focuses on developing mRNA-based vaccines to protect against potential future influenza pandemics.
- The company has initiated a Phase 1 clinical trial to evaluate the safety and immune response of its pandemic influenza vaccine candidate. This trial will help determine if the vaccine can effectively protect against different strains of the influenza virus.
- Moderna's pandemic influenza program is an important step in preparing for and potentially preventing future influenza outbreaks, which can have significant global health and economic impacts. The development of effective mRNA-based vaccines could be a game-changer in the fight against influenza pandemics.